|
|
|
| Effect of TACE Combined with HIFU on Elderly Patients with Primary Liver Cancer and its Effect on Immune Function |
| XIE Huanqin, ZHONG Wuzhuang |
| The Genenral Hospital of PLA in Guangzhou Military Area, Guangdong Guangzhou 510016, China |
|
|
|
|
Abstract Objective: To investigate the clinical efficacy of TACE (hepatic arterial chemoembolization) combined with HIFU (high intensity focused ultrasound) in elderly patients with primary liver cancer and its effect on immune function. Methods: 84 patients with primary hepatocellular carcinoma were randomly divided into control group and observation group (n = 42). The patients were randomly divided into control group and observation group. The patients in the control group were treated with TACE alone. The patients in the observation group were treated with TACE combined with HIFU. The changes of tumor volume and immune function were compared between the two groups. The median survival time and the survival rate after 3 years were compared. Results: After treatment with different methods, the tumor volume reduction and clinical treatment efficiency in the observation group were significantly better than those in the control group (P < 0.05). The median survival time and the survival rate of 1, 2 and 3 years after treatment in the observation group were significantly higher than those in the control group (P < 0.05). The levels of immune globulin IgA, IgM, IgG of patients in the observation group after treatment of 3 months were [(3.65 + 0.20) g/L], [(2.29 + 0.18) g/L], [(10.68 + 0.84) g/L], were significantly higher than those in the control group [(3.23 + 0.24) g/L], [(1.81 + 0.15 g/L]), [(8.76 + 0.67) g /L]; the difference between the two groups was statistically significant (t=8.71, 13.28, 11.58; P < 0.05); At three months after the treatment, the observation group patients complement C3 and C4 levels were [(1.49 + 0.06) g/L], [(0.34 + 0.03) g/L], the control group [(1.31 + 0.08) g/L], [(0.22 + 0.05) g/L], significant difference between the two groups (t=11.67, 13.34; P < 0.05). Conclusion: TACE combined with HIFU in elderly patients with primary liver cancer can effectively reduce the volume of the lesion, improve the immune kinetic energy of patients, improve the survival rate of patients, prolong the survival time, the effect is remarkable, worthy of clinical promotion.
|
|
|
|
|
|
[1] 朱梅珍,朱嬿蕾,叶建英.原发性肝癌患者肝动脉化疗栓塞术后肝区疼痛的观察和护理[J].护士进修杂志,2011,26(10):910~911.
[2] 罗家敏,罗小平,刘曦,等.原发性肝癌首次TACE治疗时RIPA参与肿瘤供血的影响因素分析[J].第三军医大学学报,2015,37(13):1388~1392.
[3] 吴兴军,崔林,刘建军,等.TACE、PVE联合HIFU治疗原发性肝癌的临床观察[J].现代肿瘤医学,2010,18(9):1780~1783.
[4] 李征,米登海,杨克虎.TACE联合HIFU治疗原发性肝癌的Meta分析[J].循证医学,2013,13(5):292~299.
[5] 王智,冉立峰.肝动脉化疗栓塞术后联合高能聚焦超声治疗晚期肝癌80例临床研究[J].重庆医学,2012,41(12):1160~1162.
[6] 付斯瑜,任汝仙,王美江.肝动脉灌注化疗栓塞联合高强度聚焦超声治疗中晚期原发性肝癌的临床观察[J].中国药房,2015,26(35):4978~4980.
[7] 黄耀,张卫星.HIFU、TACE治疗原发性肝癌对患者免疫功能影响的比较[J].浙江临床医学,2010,12(4):337~339.
[8] 许涛,景红霞,李林均,等.TACE、IMRT、HIFU联合DC-CIK治疗局部晚期原发性肝癌的效果[J].广东医学,2016,37(12):1846~1849.
[9] 马存凯.经肝动脉化疗栓塞术联合高强度超声聚焦刀治疗中晚期肝癌临床疗效观察[J].重庆医科大学学报,2013,38(2):179~182.
[10] 袁选举,陈萍,曹风军.高强度超声聚焦刀联合鸦胆子油乳介入治疗中晚期肝癌35例临床观察[J].临床和实验医学杂志,2013,12(21):1765~1767.
[11] 纪岩磊,韩真,邵丽梅.经肝动脉化疗栓塞术、经门静脉化疗栓塞术联合高强度聚焦超声治疗门静脉癌栓的临床研究[J].介入放射学杂志,2015,24(3):256~260.
[12] 龚文,李文仿,冉立峰.TACE联合HIFU治疗老年原发性肝癌的临床研究[J].重庆医学,2016,45(2):173~175.
[13] 陶超超,张鸿文,吴纪瑞.原发性肝癌TACE术后肺部炎症的影像表现及原因分析[J].介入放射学杂志,2012,21(12):1038~1041.
[14] 骆红霞,李进,李月翠,等.白虎汤对原发性肝癌TACE术后患者MMP-1、MMP-3、MMP-9蛋白酶的影响及其临床意义[J].中华中医药学刊,2016,34(2):380~383.
[15] 缪建春,郭予武,杨泰源.肝动脉栓塞化疗、聚乙二醇干扰素α2b和人参皂苷Rh2联合治疗HBV相关原发性肝癌临床研究[J].免疫学杂志,2013,29(7):639~641.
[16] 许涛,景红霞,李林均,等.IMRT联合HIFU治疗手术及TACE术后复发原发性肝癌的临床研究[J].重庆医学,2016,45(36):5088~5090. |
|
|
|
2017, Vol. 23 
